FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 11th. The shares were sold at an average price of $24.00, for a total value of $156,000.00. Following the completion of the sale, the vice president now owns 138,748 shares of the company’s stock, valued at $3,329,952. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Pat Cotroneo also recently made the following trade(s):

  • On Monday, December 12th, Pat Cotroneo sold 2,344 shares of FibroGen stock. The shares were sold at an average price of $22.05, for a total value of $51,685.20.

Shares of FibroGen, Inc (NASDAQ:FGEN) opened at 25.50 on Friday. The firm’s 50-day moving average price is $21.66 and its 200 day moving average price is $19.29. The company’s market capitalization is $1.61 billion. FibroGen, Inc has a 1-year low of $14.38 and a 1-year high of $25.65.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 8th. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.21. The firm earned $30.10 million during the quarter, compared to analyst estimates of $24.30 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Equities analysts predict that FibroGen, Inc will post ($0.99) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

COPYRIGHT VIOLATION NOTICE: This report was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another site, it was illegally copied and republished in violation of United States & international copyright & trademark law. The correct version of this report can be accessed at http://www.dailypolitical.com/2017/01/14/fibrogen-inc-fgen-vp-pat-cotroneo-sells-6500-shares-of-stock.html.

Several large investors have recently modified their holdings of the company. Hillhouse Capital Management Ltd. bought a new stake in shares of FibroGen during the third quarter valued at about $10,612,000. Vanguard Group Inc. raised its stake in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the last quarter. Top Ace Asset Management Ltd bought a new stake in shares of FibroGen during the third quarter valued at about $5,121,000. Candriam Luxembourg S.C.A. raised its stake in shares of FibroGen by 77.5% in the third quarter. Candriam Luxembourg S.C.A. now owns 481,000 shares of the biopharmaceutical company’s stock valued at $9,957,000 after buying an additional 210,000 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of FibroGen by 371.5% in the second quarter. American Century Companies Inc. now owns 230,019 shares of the biopharmaceutical company’s stock valued at $3,775,000 after buying an additional 181,235 shares during the last quarter. Institutional investors own 48.23% of the company’s stock.

Several equities research analysts recently issued reports on FGEN shares. Leerink Swann reiterated a “buy” rating and issued a $52.00 price target on shares of FibroGen in a research note on Wednesday, November 9th. Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research note on Friday, November 11th.

About FibroGen

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.